Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. for an upfront payment of $820 million. Actio Biosciences is now a wholly-owned subsidiary of Jazz, adding ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to Jazz's rare disease pipeline.